| 9.01 -0.99 (-9.9%) | 11-11 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.28 | 1-year : | 12.46 |
| Resists | First : | 9.66 | Second : | 10.67 |
| Pivot price | 9.64  |
|||
| Supports | First : | 8.02 | Second : | 6.68 |
| MAs | MA(5) : | 9.01 | MA(20) : | 9.83 |
| MA(100) : | 10.22 |
MA(250) : | 10.17 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 37.1 | D(3) : | 37.1 |
| RSI | RSI(14): 35.4 | |||
| 52-week | High : | 10.67 | Low : | 8.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VCKA ] has closed above bottom band by 26.9%. Bollinger Bands are 872% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.44 - 10.49 | 10.49 - 10.53 |
| Low: | 8.4 - 8.45 | 8.45 - 8.49 |
| Close: | 8.93 - 9.01 | 9.01 - 9.08 |
As of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.
Fri, 11 Nov 2022
Shares of newly public biotech Scilex climb 4% following SPAC merger (NASDAQ:SCLX) - Seeking Alpha
Thu, 10 Nov 2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and ... - GlobeNewswire
Tue, 30 Aug 2022
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP ... - GlobeNewswire
Tue, 14 Jun 2022
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG ... - GlobeNewswire
Thu, 05 May 2022
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American ... - GlobeNewswire
Mon, 25 Apr 2022
Dr. Henry Ji, Sorrento Therapeutics' Chairman and CEO and Scilex Holding Company's Executive Chairman, to ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 17 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 94.9 (%) |
| Shares Short | 188 (K) |
| Shares Short P.Month | 160 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -0.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -300.34 |
| PEG Ratio | 0 |
| Price to Book value | -15.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -130.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|